# A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

> **NCT07635914** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 382 (estimated)

## Conditions studied

- Resistant Hypertension

## Interventions

- **DRUG:** Aprocitentan tablets(SYH9108)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07635914
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2029-12-28
- **Final completion:** 2030-05-31
- **Target enrollment:** 382 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635914, "A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07635914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*